Introduction and Objective: This pilot study aimed to examine feasibility and acceptability of a telehealth DSMES intervention, Deaf Diabetes Can Together (DEDICATE), to support Deaf and hard of hearing (DHH) adults with type 1 and type 2 diabetes.Methods: Diabetes DHH Participants completed a 10- to 12-week multicomponent telehealth intervention in ASL consisting of DSMES ASL […]
Read MoreMonth: June 2026
1329-OR: Interlaboratory Validation and Method Comparison of a Novel LC-MS/MS Assay for Glucagon and Oxyntomodulin
Introduction and Objective: The quantification of plasma glucagon and oxytomodulin is important in the assessment of alpha-cell function, which is impaired in patients with diabetes. We aimed to develop, validate, and transfer between laboratories a novel assay that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the sensitive and specific measurement of these highly homologous hormones.Methods: […]
Read More1315-OR: Escaping Rejection: PD–L1/HVEM–Engineered β-Cells for Durable Transplant Survival
Introduction and Objective: Islet allo-transplantation can potentially cure type 1 diabetes (T1D), but immune rejection and systemic immunosuppression remain key challenges. Inspired by cancer immunotherapy, we hypothesized that engineering islet cells with checkpoint ligands could induce transplant tolerance. Our lab previously showed that autologous β cells reverse autoimmunity in NOD mice. Here, we demonstrate proof […]
Read More
Why Drinking Alcohol Leads to Food Cravings Like Fries and Pizza
Share on PinterestNew research found that more unhealthy, savory foods were consumed on drinking days versus non-drinking days. Jovana Milanko/Stocksy Drinking alcohol may lead to increased consumption of ultra-processed savory foods. Researchers found that alcohol can amplify the FGF21 hormone, which can cause cravings for protein and savory foods. Natural cravings for protein may be […]
Read More1320-OR: SPID-Engineered Long-Acting GIPR Antagonist Antibody for Weight Maintenance and Glycemic Recovery
Introduction and Objective: Obesity is a chronic disease requiring lifelong management, yet peptide agonists face high discontinuation and rebound weight gain due to dosing burdens. Improving therapeutic persistence requires long-acting agents optimized for weight maintenance. Leveraging antibody-based half-life extension, we developed a potent GIPR antagonist. This study evaluates its cellular potency and metabolic durability in […]
Read More1314-OR: Allogeneic Islets Are Rejected by Diabetic NOD Mice while Allogeneic Neo-Islets, 3D Organoids of Islet and Mesenchymal Stromal Cells, Durably Cure Their Type 1 Diabetes without Antirejection Drugs: Mechanisms
Introduction and Objective: T1D & T2D Dysglycemia impairs intrinsic Mesenchymal Stromal Cells’ (MSCs) protective & regenerative functions including those of pancreatic Islet-intrinsic MSCs. This accelerates b-Cell loss. Replacing MSCs at high numbers within Neo-Islets (NIs) corrects the dysfunction. The MSC component in NIs exerts trophic, anti-inflammatory, auto- and allo-immune modulatory actions (survival, angiogenic, anti-fibrotic). We […]
Read More1311-OR: Achieving at Least 15% Weight Loss within 2 Years of T2D Diagnosis Is Associated with a Lower Long-Term Risk of Micro- and Macrovascular Disease: A UK Cohort Study
Introduction and Objective: Real-world studies estimating the impact of substantial weight loss (WL) on vascular events in T2D are scarce. This retrospective cohort study investigated micro- and macrovascular risk after ≥15% WL in adults with newly diagnosed T2D.Methods: Adults with T2D and obesity were identified in UK primary care data from Clinical Practice Research Datalink […]
Read More
AstraZeneca’s New Oral GLP-1 Led to 10.5% Weight Loss
Share on PinterestAstraZeneca’s new oral GLP-1 pill showed promising results for weight loss and blood sugar in a phase 2 trial. Guido Mieth/Getty Images A new GLP-1 oral medication from AstraZeneca, known as elecoglipron, lowered blood sugar levels and led to 10.5% weight loss in a phase 2b clinical trial. Experts say GLP-1 drugs in […]
Read More1312-OR: Effects of Physical Activity and Diabetes Status on Cognitive Function and Hippocampal Volume: The Bunkyo Health Study
Introduction and Objective: Diabetes mellitus (DM) is a major risk factor for cognitive decline and dementia, whereas physical activity (PA) may mitigate this risk. However, the combined effects of PA and DM on cognitive function and brain structure remain unclear. We examined whether PA modifies associations of DM with mild cognitive impairment (MCI) and hippocampal […]
Read More1344-OR: Near- and Long-Term Improvements in A1C and CGM Metrics with Dexcom CGM Use in over 7,000 Adults with Type 2 Diabetes
Introduction and Objective: There are limited data evaluating both A1C and CGM metrics on a population level. This study assessed Dexcom CGM use on these measures in adults with T2D on non-insulin (NIT), non-intensive insulin (NIIT) and intensive insulin (IIT) therapies.Methods: Truveta EHR data linked at the individual level to Dexcom CGM data were analyzed […]
Read More